Nicotinamide Riboside in LVAD Recipients

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 26, 2018

Primary Completion Date

November 26, 2018

Study Completion Date

November 26, 2018

Conditions

Heart Failure，CongestiveHeart Failure New York Heart Association Class IVMitochondrial Alteration

Interventions

DIETARY_SUPPLEMENT

Nicotinamide riboside

nicotinamide riboside supplied as 250mg capsules

Trial Locations (1)

University of Washington, Seattle

All Listed Sponsors

collaborator

American Heart Association

OTHER

lead

University of Washington

OTHER

NCT03727646 - Nicotinamide Riboside in LVAD Recipients | Biotech Hunter | Biotech Hunter